Solid Thumbs-Up on CMS Price Negotiation | 2023 Annual Managed Healthcare Executive Pharmacy Survey
Vast majority of respondents indicate that CMS price negotiation is a positive development
For years, the notion that the federal government would negotiate the prices that the Medicare program pays for drugs was seen as highly controversial and politically improbable, partly because of the adamant opposition of the pharmaceutical industry. But last year’s Inflation
Reduction Act included provisions that empowered the Centers for Medicare and Medicaid Services to negotiate drugs, starting with 10 Part D drugs in 2026.
But the controversy seems to have cooled off considerably, judging by the results of 2023 Annual Managed Healthcare Executive Pharmacy Survey. A very large majority — 88% — of the 311 respondents to the survey indicated that they see CMS price negotiation as a positive development,” and only relatively small minority — 18% — indicated agreement with the statement that “patients will lose out because fewer new drugs will be developed,” which has been one of the key messages about price negotiation from the pharmaceutical industry.
The online survey was conducted Feb. 14-28. The respondents were spread fairly evenly across the various sectors of the U.S. healthcare industry, with 20% self-identifying as working for hospitals, 22% for physician practices, 19% for pharmacy benefit managers, 16% for payer organizations, 13% for drug and device manufacturers and the rest in other sectors.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
